Skip to search formSkip to main contentSkip to account menu

1 ML TALIMOGENE LAHERPAREPVEC 100000000 UNT Injection

Known as: TALIMOGENE LAHERPAREPVEC 100 MILLION PFU/ML INJ,SUSP,1ML,VIL, TALIMOGENE LAHERPAREP 100 MIL PFU/ML 1ML, talimogene laherparepvec 100,000,000 PFU per 1 ML Injection 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

1 ML TALIMOGENE LAHERPAREPVEC 100000000 UNT Injection [Imlygic]
InjectionTALIMOGENE LAHERPAREPVEC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
Monoclonal antibodies that block the programmed death-1 (anti-PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune… 
2019
2019
Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy.
2017
2017
FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec.
61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months… 
2017
2017
Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
2017
2017
Dermoscopic Guidance of Talimogene Laherparepvec Injection for Metastatic Melanoma.
An 89-year-old woman was referred to our multidisciplinary skin oncology clinic for management of a left lower leg melanoma. The… 
2017
2017
Neoadjuvant Talimogene Laherparepvec for the Treatment of Metastatic Melanoma
Metastatic melanoma remains a difficult clinical situation for even the experienced clinician. Treatment decisions remain fairly… 
2017
2017
Beware! Live Virus in Oncologic Therapy: Talimogene Laherparepvec (TVEC) and Nursing Considerations
Review
2016
Review
2016
Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
IntroductionFew randomized controlled trials have compared new treatments for metastatic melanoma. We sought to examine the… 
Review
2016
Review
2016
NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.
Review
2016
Review
2016
Talimogene laherparepvec (T-VEC), review of a new therapy of cutaneous melanoma with genetically modified oncolytic virus
Talimogen laherparepwek (T-VEC) to pierwsza (ostatnio zarejestrowana w Unii Europejskiej) immunoterapia wirusem onkolitycznym… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)